Investor Center
Pentixapharm AG, a subsidiary of Eckert & Ziegler Group (ISIN DE0005659700; TecDAX), plans a spin-off into Pentixapharm Holding AG and a subsequent listing in the Prime Standard of the Frankfurt Stock Exchange. This page is designed to provide investors with the relevant information about the spin-off, the subsequent listing and the opportunities the company provides in the radiopharmaceutical sector.
Investment Highlights
Business model focused on innovative radiopharmaceuticals for the diagnosis and therapy of various indications (theranostics)
Institutional environment characterized by high market growth and intense M&A activity
IPO as a strategic step to secure short- and long-term financing
Lead candidate PentixaFor already in Phase III
Commercial rights to over 20 investigator-initiated studies (IIS) for accelerated pipeline development